(Q24197839)

3

0 references

author name string

Rahul Mhaskar

1

0 references

Jasmina Redzepovic

2

0 references

Otavio Augusto Camara Clark

4

0 references

Branko Miladinovic

5

0 references

Axel Glasmacher

6

0 references

Ambuj Kumar

Cochrane Database of Systematic Reviews

7

0 references

publication date

16 May 2012

0 references

published in

0 references

cites work

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Safety and efficacy of bisphosphonates beyond 24 months in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Perspective study on pamidronate in stage I multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Phase II trial of clarithromycin and pamidronate therapy in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Zoledronic acid treatment at home: safety data from an observational prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonate-associated osteonecrosis of the jaw

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

The treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Extended safety profile of oral clodronate after long-term use in primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

The role of bisphosphonates in breast and prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Renal Failure with the Use of Zoledronic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonates and jaw osteonecrosis: the UAMS experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Checking consistency in mixed treatment comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonates: mechanism of action and role in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Systematic Reviews in Health Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Borrowing strength from external trials in a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Controlling the risk of spurious findings from meta-regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Possible association between diabetes and bisphosphonate-related jaw osteonecrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonate-related osteonecrosis of the jaws: a report of three cases demonstrating variability in outcomes and morbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

An assessment of clinically useful measures of the consequences of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonates and osteonecrosis of the jaw: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Zoledronic acid in myeloma: MRC Myeloma IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Variance components analysis for pedigree-based censored survival data using generalized linear mixed models (GLMMs) and Gibbs sampling in BUGS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Management of the adverse effects associated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Investigating underlying risk as a source of heterogeneity in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

How should meta-regression analyses be undertaken and interpreted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaw associated with pamidronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

Effects of intermittent administration of pamidronate on the mechanical properties of canine cortical and trabecular bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Pamidronate: an unrecognized problem in gastrointestinal tolerability

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Long-Term Effects of Dichloromethylene Diphosphonate (Cl2 DP) on skeletal Lesions in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3 cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): report of a case

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

[Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Anti-myeloma activity of pamidronate in vivo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Osteonecrosis of the jaw and bisphosphonates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Images in clinical medicine. Bisphosphonate-associated osteonecrosis of the jaw

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

New therapeutic protocol in the treatment of avascular necrosis of the jaws

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Bisphosphonate-associated osteonecrosis of the auditory canal

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Effect of daily etidronate on the osteolysis of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Palliative pamidronate treatment in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Imaging findings of bisphosphonate-associated osteonecrosis of the jaws

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021

Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003188.PUB3

7 January 2021